Myopia Profile

Vyluma

The word “Vyluma,” originates from different languages across the globe and carries the meaning to expand and open to light. Vyluma, a biopharmaceutical company, specializes in creating innovative eye drop treatments for global ophthalmic diseases. Their dedicated team aims to enhance patients' quality of life by preserving their vision through transformative therapeutics. Working alongside eye care clinicians, they strive to revolutionize the current standard of care with with regard to myopia management.  

Vyluma sponsored articles in Myopia Profile.

The technology of topical atropine - Q&A with Dr Houman Hemmati and Dr Kumaresh SoppimathLearn about NVK002, a preparation of atropine that undergoes a commercial manufacturing process instead of compounding. Read Full Article The latest research on atropine: efficacy, ideal candidates, and safetyNVK002 is a formulation of atropine developed by Vyluma: this article explores the newest insights gained. Read Full Article What's in the atropine bottle? Q&A With Professor Mark BullimoreWe asked Professor Mark Bullimore some fascinating questions about atropine, from concerns with compounding to the ideal atropine drop.Read Full Article
The technology of topical atropine - Q&A with Dr Houman Hemmati and Dr Kumaresh SoppimathLearn about NVK002, a preparation of atropine that undergoes a commercial manufacturing process instead of compounding. Read Full Article

Vyluma resources

MyMyopia.com website

MyMyopia.com is a website and awareness campaign that provides important educational information for parents regarding childhood myopia. The website also provides eye care professionals with tools and resources to educate their patients on the childhood myopia epidemic with a goal of improving the lifelong ocular health of children worldwide.

Visit MyMyopia